Journal of Diabetes Research

Journal of Diabetes Research / 2020 / Article
Special Issue

Diabetes Mellitus and its Cardiovascular Complications: New Insights into an Old Disease 2020

View this Special Issue

Research Article | Open Access

Volume 2020 |Article ID 3634974 | https://doi.org/10.1155/2020/3634974

Qian Wang, Xuefei Tian, Wei’e Zhou, Yan Wang, Hailing Zhao, Jialin Li, Xuefeng Zhou, Haojun Zhang, Tingting Zhao, Ping Li, "Protective Role of Tangshen Formula on the Progression of Renal Damage in db/db Mice by TRPC6/Talin1 Pathway in Podocytes", Journal of Diabetes Research, vol. 2020, Article ID 3634974, 19 pages, 2020. https://doi.org/10.1155/2020/3634974

Protective Role of Tangshen Formula on the Progression of Renal Damage in db/db Mice by TRPC6/Talin1 Pathway in Podocytes

Academic Editor: Claudio De Lucia
Received16 Feb 2020
Revised11 Aug 2020
Accepted29 Aug 2020
Published17 Sep 2020

Abstract

Tangshen Formula (TSF) is a Chinese Medicine formula that has been reported to alleviate proteinuria and protect renal function in humans and animals with diabetic kidney disease (DKD). However, little is known about its mechanism in improving proteinuria. The dysregulation of podocyte cell-matrix adhesion has been demonstrated to play an important role in the pathogenesis and progression of proteinuric kidney diseases including DKD. In the present study, the underlying protective mechanism of TSF on podocytes was investigated using the murine model of type 2 DKD db/db mice in vivo and advanced glycation end products (AGEs)-stimulated primary mice podocytes in vitro. Results revealed that TSF treatment could significantly mitigate reduction of podocyte numbers and foot process effacement, reduce proteinuria, and protect renal function in db/db mice. There was a significant increase in expression of transient receptor potential canonical channel 6 (TRPC6) and a decrease in expression of talin1 in podocytes of db/db mice. The results of AGEs-stimulated primary mice podocytes showed increased cell migration and actin-cytoskeleton rearrangement. Moreover, primary mice podocytes stimulated by AGEs displayed an increase in TRPC6-dependent Ca2+ influx, a loss of talin1, and translocation of nuclear factor of activated T cell (NFATC) 2. These dysregulations in mice primary podocytes stimulated by AGEs could be significantly attenuated after TSF treatment. 1-Oleoyl-2-acetyl-sn-glycerol (OAG), a TRPC6 agonist, blocked the protective role of TSF on podocyte cell-matrix adherence. In conclusion, TSF could protect podocytes from injury and reduce proteinuria in DKD, which may be mediated by the regulation of the TRPC6/Talin1 pathway in podocytes.

1. Introduction

Diabetic kidney disease (DKD) is one of the most common and severe complications of diabetes mellitus and is characterized by proteinuria and renal function impairment. DKD is the major cause of end-stage renal disease (ESRD) worldwide [1]. Accumulating evidence suggests that podocyte injury is a typical manifestation and a core event in the progression of DKD [2]. Podocytes are important components for glomerular filtration barrier integrity and maintenance of size selectivity in protein filtration. Changes in podocyte number and/or structure of foot processes have been demonstrated to be the main cause leading to glomerular proteinuria [3]. Under physiologic conditions, the podocyte actin backbone is well organized to maintain their normal morphology and function. Numerous studies on podocytes have shown that actin-cytoskeletal disorganization and related protein damage induced by multiple pathogenic factors lead to podocyte injury [4, 5]. Cell-matrix adhesion core structure complexes, including integrins/talins/actin, are crucial for maintaining the podocyte actin cytoskeleton. These adhesion complexes allow podocytes to attach tightly to the glomerular basement membrane (GBM) to preserve the integrity of the glomerular filtration barrier. Any deficit in the structural components can disturb podocyte adhesion and lead to the disorganization of the actin cytoskeleton [6].

As a cell-matrix adhesion core structure complex, talin1 impairment can lead to integrin dysfunction, which is associated with a variety of pathologies, including thrombosis, stroke, and cancer metastasis [7]. Tian and colleagues [8] demonstrated that mice lacking talin1 specifically in podocytes displayed severe proteinuria, decreased podocyte adhesion, significant actin-cytoskeletal disorganization, foot process effacement, and progressive renal failure. Transient receptor potential canonical channel 6 (TRPC6) is a nonselective Ca2+ channel protein, which has been reported to be closely related to the cleavage of talin1 [9]. Mutation of the TRPC6 gene in podocytes was first reported by Winn et al. in patients with focal segmental glomerulosclerosis (FSGS), suggesting the potential importance of TRPC6-mediated Ca2+ dynamics for podocyte function [10]. More and more studies have shown that aberrant changes in TRPC6 in podocytes lead to proteinuria development and progression of DKD, the mechanism by which may involve the rearrangement of the podocyte actin-cytoskeleton [11, 12]. TRPC6-dependent Ca2+ accumulation has been reported to lead to podocyte injury characterizing FSGS through reduced talin1 expression [13]. Furthermore, knockdown of TRPC6 also results in decreased cleavage of talin1 [9]. However, it is unclear how the podocyte TRPC6/Talin1 signaling pathway affects the development and progression of DKD; thus, this mechanism needs to be investigated.

Tangshen Formula (TSF) is a Chinese Medicine formula that is effective in treating DKD and is based on the empirical evidence of Chinese physicians [14]. TSF is comprised of seven herbs: astragalus root, burning bush twig, rehmannia root, bitter orange fruit, cornus fruit, rhubarb root and rhizome, and notoginseng root and rhizome. Patients with stage III-IV DKD who were treated with one component of TSF, astragalus root injection, experienced improved renal function and decreased proteinuria excretion compared with those in a control group [15]. A decoction made from another TSF component, rehmannia root, was found in vitro to dramatically suppress the production of AGEs induced by inflammation [16]. Through liquid chromatography-mass spectrometry (LC-MS), we have successfully detected 40 compounds in TSF and 12 compounds in the serum of TSF-treated mice (supplementary Tables S1 and S2). Six compounds, including loganin, neohesperidin, naringenin, calycosin-7-O-β-D-glucoside, naringenine-7-rhamnosidoglucoside, and aloe-emodin, were selected to describe the quality of TSF by comparing the high-performance liquid chromatography (HPLC) fingerprints of 10 sample batches [17, 18]. The results confirmed that these six compounds exhibit renal protective effects [1926]. Our preliminary multicenter clinical trial [14] and various animal models of DKD [2729] showed that TSF has significant effects in reducing proteinuria and protecting renal function. However, little is known about its potential mechanism in improving proteinuria and its effects on podocytes. In the present study, we found that TSF mitigated podocyte number loss and foot process effacement reduced proteinuria, and protected renal function in db/db mice, a classic genetic model of type 2 diabetes that has clinical and histologic features of DKD resembling changes in humans [30]. Our results further showed that TSF might alleviate proteinuria mediated by the regulation of the TRPC6/Talin1 pathway in podocytes, following enhancement of the podocyte-matrix adhesion ability.

2. Materials and Methods

2.1. Herbal Formulation and Reagents

TSF (Lot number180408) was prepared and standardized by the Beijing Institute of Clinical Pharmacy, Beijing, China. TSF is composed of seven herbs: astragalus root (Astragalus membranaceus (Fisch) Bge.), burning bush twig (Euonymus alatus (Thunb.) Siebold.), rehmannia root (Rehmannia glutinosa (Gaertn.) Li-bosch.), bitter orange fruit (Citrus aurantium L.), cornus fruit (Cornus officinalis Sieb & Zucc.), rhubarb root and rhizome (Rheum palmatum L.), and notoginseng root and rhizome (Panax Notoginseng (Burk.) F. H. Chen) in the ratio of 10 : 5 : 4 : 3.4 : 3 : 2 : 1 (). TSF was prepared as described in the Chinese Pharmacopeia, 2015. Six components, including loganin, neohesperidin, naringenin, calycosin-7-O-β-D-glucoside, naringenine-7-rhamnosidoglucoside, and aloe-emodin, were identified in the chemical fingerprint of TSF for quality control as previously described [18]. Irbesartan (J20171089) was purchased from Sanofi Pharmaceutical (Hangzhou, ZJ, China). For the animal experiments, both TSF (0.36 g/mL) and irbesartan (2.25 mg/mL) were dissolved in 0.5% carboxymethylcellulose sodium (CMC-Na).

Antibodies used in this study were as follows: TRPC6 (ab62461) (the specificity of the anti-TRPC6 antibody has been tested by MPC5 cells and Trpc6 siRNA in Figure S1), WT1 (ab89901), AGE-BSA (ab51995), fibronectin antibody (ab2413), collagen type I (ab34710), and collagen type IV (ab6586), all purchased from Abcam (Cambridge, MA, USA). siRNA against TRPC6 was purchased from Shanghai Generay Biotech (Shanghai, China). Nephrin antibody (GP-N2) was obtained from Progen (Heidelberg, Germany). Talin1 antibody (14168-1-AP), NFATC2 (nuclear factor of activated T cell) antibody (22023-1-AP), NFATC3 antibody (18222-1-AP), integrin β1 antibody (26918-1-AP), and GAPDH antibody (60004-1-Ig) were purchased from Proteintech (Wuhan, HB, China). Paxillin antibody (sc-365379) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES) (15630080), RPMI 1640 medium (no phenol red) (11835030), penicillin-streptomycin (15140122), sodium pyruvate (11360070), sodium bicarbonate (25080094), fetal bovine serum (FBS) (10099141), Alexa Fluor 488 Phalloidin (A12379), Alexa Fluor 594 goat anti-guinea pig secondary antibody (A11076), Alexa Fluor 594 goat anti-rabbit secondary antibody (A11012), and Alexa Fluor 488 goat anti-rabbit secondary antibody (A11008) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 1-Oleoyl-2-acetyl-sn-glycerol (OAG) (O6754), Hanks’ balanced salt solution (HBSS) (H6648), and collagen type I solution from rat tail (C3867) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Collagenase A (11088793001) and DNase (04716728001) were purchased from Roche (Mannheim, Germany). CMC-Na (C8621) was purchased from Solarbio (Beijing, China). ELISA Quantitation Set kit (E101) was obtained from Bethyl Laboratories (Montgomery, TX, USA). Fluo-4-AM (S1060), ionomycin (S1672), EDTA (ST066), and MTT Cell Proliferation and Cytotoxicity Assay Kit (C0009) were purchased from Beyotime Biotechnology (Shanghai, China). SAR7334 (HY-15699) was purchased from MedChemExpress (Shanghai, China).

2.2. Assay of the Compounds in TSF and in the Mouse Serum Treated with TSF Determined by UHPLC-MS/MS

The 1 g of dried TSF compound prescription power was extracted with methanol-water (25 mL, 75 : 25, ) using an FS30 ultrasonic sonicator (Fisher Scientific, Pittsburg, PA, USA) at 40 kHz and 100 W for 30 minutes at room temperature. A 10 μg of the extract was injected onto the analytical column for analysis. For the preparation of mouse serum sample treated with TSF, the 8-week-old male C57BL/6J mouse was gavaged with TSF at the dosage of 2.4 g/kg body weight, the serum sample was collected after 24 hours administration. The 150 μL of mouse serum sample was mixed with 400 μL methanol, following by centrifuging at 14480 g for 10 minutes at 4°C. The supernatant was evaporated to dryness by Centrivap Concentrator (LABCONCO, USA), then 400 μL methanol was added. After centrifuging at 14480 g for 20 minutes at 4°C, supernatant was collected for analysis.

The prepared samples were analyzed using the ultrahigh performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). Briefly, UHPLC-MS/MS analysis was performed using Q Exactive Plus High Resolution Mass Spectrometer (THERMO, USA) equipped with Ultimate 3000 (DIONEX, THERMO, USA), and Acquity™ UPLC BEH C18 column ( mm, 1.7 μm) (Waters, USA). The optimized chromatographic conditions were achieved at a flow rate of 0.3 mL/min with a mobile phase consisting of acetonitrile (mobile phase A) and 0.1% formic acid solution (mobile phase B). The diode array detector (DAD) was set at 280, 254 nm for real-time monitoring of the peak intensity and full spectra (190-650 nm). The following conditions were applied for MS: capillary temperature 320°C, spray voltage 3.5 kV for ESI+analysis; and capillary temperature 320°C, spray voltage -3.5 kV for ESI-analysis. The mass scan range was set to 100-1500. The resolution of the Orbitrap was set to 70000. The resolution of dd-MS2 was set to 17500; CE was set to 20 : 40 : 60. The peak picking and alignment were processed using Sieve software (V1.2, Thermo Fisher Scientific, USA) applying a mass width of 0.02 Da and a retention time width of 0.5 minutes.

2.3. Animals and Experimental Design

Eight-week-old male C57BLKS/JLeprdb/db mice () weighing  g and db/m mice () weighing  g were purchased from the Peking University Laboratory Animal Center (Beijing, China). Since the misty (m) gene has a greater effect on the metabolism of mice, m/m mice are 8% shorter and weigh 15% less than controls and have less inguinal adipose mass and complete loss of brown fat [31]. Therefore, the db/m mice are usually used as the control group in db/db mice studies [32]. All mice were maintained inhouse under the following specific pathogen-free conditions: °C controlled temperature, 65-75% relative humidity, a regular 12-hour light/dark cycle, and received standard laboratory chow and water ad libitum. After 2 weeks of acclimation, the db/m mice were used as controls (designated db/m). db/db mice were randomly assigned into three groups (, per group): db/db mice (designated db/db), db/db mice treated with TSF (3.6 g/kg/day) (designated db/db + TSF), and db/db mice treated with irbesartan (22.5 mg/kg/day) (designated db/db + Irbesartan). The db/m and db/db groups were each given equal volume of 0.5% CMC-Na, gavage administration. All drugs were administered once daily by gastric gavage. Dose of TSF was adjusted based on our previous studies and standard conversion formulas [14, 33]. Body weight was recorded weekly during the study period. Urine was collected at the beginning of treatment and the 12th week. The mice were sacrificed after 12 weeks of treatment. After overnight fasting, the serum and tissue samples were collected rapidly for further analysis. All experimental animal procedures were in accord with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (2011 edition). The protocol was approved by the Ethics Committee of the China-Japan Friendship Institute of Clinical Medical Sciences (Approval no.13005).

2.4. Biochemistry Measurements

Mouse urine samples were collected using metabolic cages (Fengshi Inc., Suzhou, JS, China) [27]. Urine albumin was quantified in duplicates using the Mouse Albumin ELISA Kit according to the manufacturer’s protocol (Bethyl Laboratories). Urine creatinine was measured in duplicate for each sample using an automatic analyzer (Abbott Diagnostics, Abbott Park, IL, USA).

2.5. Histologic Assessment of Glomerular Injury

Kidney tissues were fixed in 10% formalin, embedded in paraffin sections (2-3 μm), and stained with periodic acid-Schiff (PAS) and periodic acid-silver methenamine (PASM). Kidney ultrastructure was detected by transmission electron microscopy (TEM) (JEOL-100CXII, JEOL, Tokyo, Japan). Kidney tissues (1 mm3) were fixed with 2.5% glutaraldehyde at 4°C for 24 hours and embedded in epoxy resin. Ultrathin sections were sliced and stained with uranyl acetate and lead citrate. Twenty glomerular cross-sections (with the vascular pole and the urinary pole on the same plane) per sample were randomly selected under a 400x light microscope (Olympus, Tokyo, Japan), and the areas of each glomerulus and mesangial matrix were measured using Image-Pro Plus 6.0 software (Media Cybernetics, Warrendale, PA, USA) by two pathologists in a double-blinded manner. Thirty glomerular capillaries per sample were randomly selected (magnification 12000x) to measure GBM thickness, podocyte foot process width, and the number of foot processes per micron in a double-blinded manner [34, 35].

2.6. Immunohistochemistry and Immunofluorescence

Paraffin-embedded mice kidney sections were deparaffinized with xylene following hydration with ethanol. Antigen retrieval was induced by microwave following washing with 1× phosphate buffer saline (PBS) as previously described [8]. Sections were incubated overnight at 4°C with anti-fibronectin antibody (1 : 500), anti-collagen type I antibody (1 : 1000), anti-collagen type IV antibody (1 : 400), anti-nephrin antibody (1 : 2000), and anti-WT1 antibody (1 : 1000). Subsequently, the sections were incubated with secondary antibodies and counterstained with hematoxylin for the nuclei. Images were captured under the light microscope and then measured by Image-Pro Plus 6.0 software. For immunofluorescence, paraffin-embedded kidney sections were incubated in blocking buffer (5% BSA in 1× PBS) for 1 hour at room temperature and stained with antibodies in the following concentration: anti-nephrin antibody (1 : 100) and secondary antibody Alexa Fluor 594 goat anti-guinea (1 : 200). Costaining was with the following antibodies: anti-TRPC6 antibody (1 : 100), anti-talin1 antibody (1 : 100), anti-WT1 antibody (1 : 100), and secondary antibody Alexa Fluor 488 goat anti-rabbit (1 : 200). For cell immunofluorescence, primary mice podocytes on collagen type I-coated coverslips were washed with 1× PBS and fixed with 4% paraformaldehyde for 15 minutes. The cells were permeated with 0.5% Triton X-100 for 20 minutes at room temperature. The cells were blocked with 5% BSA in 1× PBS for 1 hour and stained with antibodies in the following concentration: anti-TRPC6 antibody (1 : 100), anti-WT1 antibody (1 : 100), anti-Talin1 antibody (1 : 50), anti-paxillin antibody (1 : 100), anti-NFATC2 antibody (1 : 100), anti-NFATC3 antibody (1 : 100), and secondary antibody Alexa Fluor 488 goat anti-rabbit (1 : 300). The resulting images were obtained by a fluorescent inverted microscope (Olympus).

2.7. Isolation of Primary Mice Podocytes

The protocol for primary mice podocytes culture isolated from newborn mice was performed as previously described [8]. The freshly removed kidneys from the C57BL/6J newborn mice (Beijing HFK Bioscience, Beijing, China) were minced into very small pieces in a 10 cm dish. After digestion for 30-45 minutes in a collagenase solution (5 mg/mL collagenase A and 1 : 10 DNase) at 37°C and 5% CO2 incubation, the resulting suspension was filtered with a 70 μm BD Falcon cell strainer (Corning Life Sciences, Corning, NY, USA). The filtered solution (glomerular cells) was then plated onto the 10 cm culture dish coated with collagen type I to total 1640 RPMI medium with 10% FBS, 1% penicillin-streptomycin, 10 mM HEPES, 0.075% sodium bicarbonate, and 1 mM sodium pyruvate. The primary mice podocytes were harvested by separating the glomerular cells with 0.25% trypsin (Invitrogen) and then sieving through a 40 μm BD Falcon cell strainer. Cells were cultured in a humidified incubator with 5% CO2 at 37°C and used at passages 1 or 2 for all experiments. The purity of the primary mice podocytes was 95% as determined by immunofluorescence staining with the WT-1 antibody, a specific marker of podocytes [36].

2.8. Cell Treatments

To investigate the role of AGEs, the primary mice podocytes were exposed to AGE-BSA for 24 hours sequentially at 60, 80, 100, and 120 μg/mL. Equal amounts of BSA were added to the control cells. After successfully producing the podocyte injury model induced by AGEs, the cells were treated with a series of concentrations (250, 500, and 750 μg/mL) of TSF for 24 hours with AGE-BSA (100 μg/mL). The cells cultured with BSA (100 μg/mL) served as controls. SAR7334 (0.1 μmol/L) was used as a TRPC6 inhibitor while OAG (100 μmol/L) as a TRPC6 agonist.

2.9. Determination of Cell Viability

The effect of TSF on cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. After being starved with 1640 RPMI medium without FBS overnight, the primary mice podocytes ( cells/well) growing in 96-well plates were incubated with BSA (100 μg/mL) and TSF (0, 100, 250, 500, 750, and 1000 μg/mL) for 24 hours. Each well was incubated with 10 μL MTT solution (5 mg/mL) for 4 hours in a cell culture incubator. Subsequently, 100 μL formazan lysate was added to each well and measured at 570 nm with a microplate reader (Thermo Fisher Scientific). Cell viability was calculated as a percentage according to the manufacturer’s instructions.

2.10. Wound Healing Assay

The primary mice podocytes ( cells/well) were incubated in 6-well plates and were starved for 24 hours. Once the cells reached 100% confluence, an artificial linear wound (scratch) was introduced using a sterile 200 μL pipette tip. Cells were allowed to heal for 24 hours. The percentage of wound closure was calculated as using the ImageJ software 1.8.0 (National Institutes of Health, Bethesda, MD, USA) [37].

2.11. Quantitative Analysis of Changes in the Actin Cytoarchitecture of Primary Mice Podocytes

Changes in actin cytoarchitecture of primary mice podocytes were analyzed as previously described [8]. The multiplicity of different phalloidin staining patterns was grouped into four major classes and used for scoring as follows: Type A: more than 90% of cell area filled with thick cables; Type B: at least two thick cables running under the nucleus and the rest of the cell filled with fine cables; Type C: no thick cables, but some fine cables present; Type D: no cables visible in the central area of the cell. All slides were scored in a double-blinded manner; thirty cells in each slide were analyzed in three separate experiments.

2.12. Intracellular Ca2+ Determination

Intracellular Ca2+ concentration was determined using the Ca2+ fluorescent probe Fluo-4-AM. Primary mice podocytes in each group were washed three times with HBSS (no calcium, no magnesium, no phenol red) and incubated with Fluo-4-AM (5 μmol/L in RPMI 1640 medium) at 37°C for 45 minutes. Podocytes were trypsinized with 0.25% trypsin-EDTA, followed by centrifugation at 200 × g for 5 minutes. Intracellular Ca2+ level was measured and calculated using the FACScan flow cytometer (BD Biosciences, San Jose, CA, USA) [38]. Then, the cells were incubated with 5 μmol/L ionomycin in a zero Ca2+ bath (0 mmol/L Ca2+, 5 mmol/L EDTA) and 5 μmol/L ionomycin in saturating Ca2+ solution (5 mmol/L CaCl2), to measure minimal and maximal responses to Ca2+ [39].

2.13. Western Blot Analysis

Protein samples of kidney tissue and cells were extracted in RIPA lysis buffer (EpiZyme, Shanghai, China) at 4°C. Concentrations of protein were determined using BCA assay. Equal amounts of total protein were denatured for 10 minutes at 95°C. The protein lysates (25 μg) were separated in 10% or 12% polyacrylamide gels (EpiZyme) and transferred onto 0.45 μm polyvinylidene fluoride (PVDF) membranes (Millipore Sigma, Darmstadt, Germany). After blocking with 5% BSA in 1× PBS, membranes were incubated with antibodies overnight at 4°C in the following concentrations: anti-nephrin antibody (1 : 500), anti-WT1 antibody (1 : 500), and anti-talin1 antibody (1 : 500). Blots were detected using enhanced chemiluminescence (Amersham Pharmacia Biotech, Buckinghamshire, UK) with the ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA). Finally, the protein bands were quantified using the ImageJ software.

2.14. Statistical Analysis

All data were presented as the . Numbers for each experiment are displayed in the Methods or the figure legends. Statistical difference between two groups was evaluated by a 2-tailed -test. Multiple-group comparisons were evaluated using one-way ANOVA followed by Dunnett’s multiple-comparisons tests. Statistical analysis was performed by the GraphPad Prism 6.0 software (San Diego, CA, USA). A value less than 0.05 was considered statistically significant.

3. Results

3.1. TSF Reduced Proteinuria and Attenuated Renal Injury in db/db Mice

During the 12-week intervention with TSF or irbesartan, there were no obvious side effects observed in the db/db mice. The body weights between the mice of db/db group and the mice of db/db + TSF group were similar at the age of 10 weeks. TSF treatment significantly reduced the body weights of db/db mice compared with the db/db mice without treatment starting from age of 19 weeks till the end of the study. However, there were no significant changes in the body weights of db/db mice treated with irbesartan observed (Figure 1(a)). There were no changes in the kidney weights either TSF-treatment or irbesartan-treatment in the db/db mice compared to vehicle-treatment control db/db mice (Figure 1(b)).

Renal damage in db/db mice was assessed by the urine albumin-to-creatinine ratio (ACR) assay and serum creatinine levels. Compared with mice of 10 weeks of age, ACR in db/db mice was significantly decreased after 12 weeks of TSF treatment (Figure 1(c)). Moreover, TSF significantly reduced serum creatinine levels in db/db mice (Figure 1(d)). Irbesartan-treated db/db mice also showed significant improvement in ACR and serum creatinine. The typical pathologic damage changes in db/db mice, including glomerular hypertrophy, mesangial expansion, thickened GBM, and abnormal deposition of fibronectin, collagen type IV, and collagen type I, were relieved by TSF or irbesartan treatment (Figures 1(e), 1(f), and S2). Therefore, TSF could effectively alleviate proteinuria and renal injury in db/db mice, which is consistent with our previously reported results [29, 40].

3.2. TSF Improved Podocyte Injury, Reduced Expression of TRPC6 and Enhanced Expression of talin1 in db/db Mice Podocytes

To investigate the ultrastructural changes in the podocytes, transmission electron microscopy was performed. The results showed that there were a severe foot process effacement and an increased GBM thickness in the db/db mice, which was strikingly improved by either TSF or irbesartan treatment at a similar effect (Figure 2(a)). Consistent with the PASM results (Figure 1(e)), the thickened GBM in db/db mice under the electron microscopy also showed significant relief after TSF treatment. We further studied the expression of WT1 and nephrin, two specific podocyte markers, on kidney tissue of db/db mice. Our results showed that there was a significant decrease in WT1 expression, and no significant change in nephrin either in protein expression or localization (Figures 2(b) and 2(c)). Given the presenting characteristics of early DKD in db/db mice, it was speculated that partial foot process effacement of db/db mice had not seriously affected the structure of the slit diaphragm (SD) of podocytes and the related protein nephrin.

Considering reduction of WT1 represented decrease in podocyte numbers, we examined the podocyte-associated protein talin1, which is a crucial part of the podocyte-matrix adhesion structure. Results showed that there was a significant loss in talin1 protein in db/db mice and that TSF could prevent its loss (Figure 3(a)). Since talin1 expresses ubiquitously, we observed the change in talin1 in podocytes by costaining with nephrin. We found that talin1 loss was mainly concentrated in podocytes in db/db mice (Figure 3(b)). Verheijden et al. [13] reported that loss of talin1 is closely related to the abnormal expression of TRPC6. Based on this, we attempted to determine the potential changes in the expression of TRPC6 on podocytes by costaining with nephrin. Our results showed there was increased TRPC6 expression in db/db mice podocytes, which could be mitigated by TSF treatment (Figure 3(c)). This suggested that podocyte injury in db/db mice could be attributed to the loss of podocyte-specific talin1 protein, which may be associated with the increase in TRPC6 expression. Thus, TSF had a significant protective effect on podocyte talin1 in db/db mice.

3.3. TSF Alleviated Cell Migration and Actin-Cytoskeletal Disorganization in AGEs-Stimulated Primary Mice Podocytes

To further understand the role of talin1 and TRPC6 in podocytes and the mechanism of TSF, we continued our investigation by culturing primary mice podocytes in vitro. AGEs are involved in the pathogenesis of DKD and are closely related to the extent of podocyte injury [41, 42]. In combination with the AGEs deposition found in the kidney tissue of db/db mice, we used AGEs to establish a primary mice podocyte injury model in vitro. Loss of podocyte talin1 results in a reduction in cell adhesion, an increase in cell migration, and actin-cytoskeletal disorganization [8]. TRPC6-dependent Ca2+ accumulation has been found to cause podocyte injury through the loss of talin1 in human and experimental FSGS [13]. Therefore, we hypothesize that the lack of talin1 in type 2 DKD model db/db mice may also occur following TRPC6 activation, and TSF may have a certain degree of therapeutic effect through this mechanism. Cells lacking talin1 have impaired abilities on reduced cell adhesion, spreading, and migration [43]. Moreover, the changes in different phalloidin staining patterns in podocytes have been shown to be associated with podocyte migration ability [44]. We observed their migration ability through the wound healing assay after starving for 24 hours. Given that podocytes are terminally differentiated epithelial cells lacking the proliferative ability and our results, the effects of podocyte proliferation on the wound healing assay are less likely especially under the same experimental conditions. The most obvious migration occurred in primary mice podocytes after AGEs stimulation at a dose of 100 μg/mL for 24 hours (Figures 4(a) and 4(b)). The cytotoxicity of TSF on primary mice podocytes was analyzed using MTT at a concentration range of 100 μg/mL to 1000 μg/mL. Results showed that TSF treatment at a concentration of up to 750 μg/mL had no effect on the cells (Figure 4(c)). MTT results revealed that TSF treatment with AGEs (100 μg/mL) at a concentration of up to 750 μg/mL had no effect on primary mice podocytes (Figure 4(d)). TSF mitigated podocyte migration induced by AGEs in a dose-dependent manner (250, 500, and 750 μg/mL) (Figures 4(e) and 4(f)).

Based on this, we observed podocyte morphology as related to migration. Compared with the control group, podocytes in the AGEs-stimulated group appeared to have the more obvious formation of lamellipodia and filopodia (Figures 5(a) and 5(b)), which are associated with increased cell motility and actin rearrangement.

Immunofluorescence labeling of the podocyte nucleus with WT1 and F-actin with phalloidin showed that AGEs caused actin-cytoskeletal disorganization in cultured primary mice podocytes. The AGEs-stimulated primary mice podocytes had fewer cells with types A (>90% of cell area filled with thick cables) and B (at least two thick cables running under the nucleus and rest of cell area filled with fine cables) staining patterns and more cells in type C (no thick cables, but some cables present), and type D (no cables visible in the central area of the cell) pattern when compared with control podocytes, and these effects were decreased by TSF (500 μg/mL) (Figures 5(c) and 5(d)). In short, TSF inhibited cell migration and attenuated actin-cytoskeletal disorganization in primary mice podocytes stimulated by AGEs.

3.4. TSF Alleviated Podocyte Injury by Improving Cell-Matrix Adhesion Ability through Regulation of TRPC6/Talin1 Pathway

We explored the relationship between AGEs and TRPC6 by calculating the relative concentration of Ca2+ in AGEs-stimulated primary mice podocytes using Ca2+-sensitive dye fluo-4-AM. Results showed that compared with the BSA group, the BSA+TSF group had no effect on podocyte intracellular Ca2+ concentration. However, there was a significant increase in Ca2+ level in AGEs-treated podocytes compared with the control group, while in the groups that were pretreated with TSF and SAR7334 (0.1 μmol/L), a potent and specific cell-membrane permeable inhibitor of TRPC6 [45], there was a significant decrease in Ca2+ level compared with AGEs-treated podocytes (Figure 6(a)). Also, there was a decrease in talin1 in AGEs-stimulated primary mice podocytes, accompanied by an increase in the expression of TRPC6 (Figures 6(b) and 6(c)). The loss of talin1 has been shown to affect the expression of some focal adhesions; thus, we initially evaluated the expression of integrin β1 and paxillin, two kinds of intracellular anchor proteins in cell-matrix adhesion that can bind directly to actin. The results showed a decrease in integrin β1 and paxillin in AGEs-treated podocytes (Figures 6(c) and 6(d)). TSF protected talin1, integrin β1, and paxillin from loss and reduced expression of TRPC6, and all phenomena could be attenuated by OAG (100 μmol/L), agonist of TRPC6. These results showed that TSF could improve cell-matrix adhesion ability and reduce TRPC6-dependent Ca2+ accumulation in AGEs-stimulated primary mice podocytes. We also observed that the protective effect of TSF on podocyte actin fibers was inhibited by OAG (Figures 7(a) and 7(b)). This indicates that TRPC6 plays an important role in maintaining the stability of the podocyte actin-cytoskeleton and that TSF could alleviate TRPC6-dependent Ca2+ accumulation mediated actin-cytoskeletal disorganization and increase the cell-matrix adhesion ability in podocytes.

The downstream signaling pathway cascade of TRPC6 involves a Ca2+-dependent Calpain/Calcineurin signal transduction, which usually activates NFATCs. NFATC family members (NFATC1 through NFATC4) can be dephosphorylated by Calpain/Calcineurin signaling, resulting in their translocation to the nucleus to exert their function. The important transcriptional target of NFATCs is TRPC6 itself, which results in a harmful feedforward loop. In our study, we initially observed the expression of NFATC2 and 3 in AGEs-stimulated primary mice podocytes. Immunofluorescence morphology results revealed that AGEs-stimulated podocytes increased the percentage of NFATC2 translocated to the nucleus rather than NFATC3, and translocation could be reduced by TSF, while OAG attenuated its efficacy (Figures 8(a) and 8(b)). Therefore, we initially concluded that TSF reduced TRPC6-dependent Ca2+ accumulation, loss of talin1, and NFATC 2 nuclear translocation in primary mice podocytes stimulated by AGEs.

4. Discussion

In this study, a decreasing trend in the podocyte marker protein nephrin in db/db mice was observed; although, there was no significant difference in protein expression and localization compared with db/m control mice. The reduction in podocyte WT1 protein was more significant. Excluding some hereditary kidney diseases, foot process effacement is thought to help damaged podocytes attach to GBM by actin-cytoskeleton rearrangement, covering the exposed GBM due to partial podocyte exfoliation; it is an adaptive and reversible reaction to injury stimuli [46]. If the actin-cytoskeleton is repaired, early podocyte damage can be recovered to allow the foot process to branch again into their interdigitating pattern [2]. Thus, we hypothesized that partial foot process effacement of db/db mice in this study had not seriously affected the structure of the SD of podocytes and the related protein nephrin. The decrease in WT1-positive cells in glomeruli suggests a partial loss of podocytes, which allows us to focus on the cell-matrix adhesion structure.

The decrease of podocyte number is the strongest predictor of DKD progression. Podocyte apoptosis and detachment are the possible reasons for the loss of podocyte. Because the former is rarely observed in in vivo studies, podocyte loss can be attributed to detachment caused by podocyte adhesion failure [47, 48]. Podocytes adhere to the GBM by combining the actin cytoskeleton with the heterodimeric transmembrane integrin adhesion receptors. There are 18 kinds of α subunits and 8 kinds of β subunits, which can form 24 integrins in different combinations. Since the integrin cytoplasmic domain lacks actin-binding sites and catalytic activity, it is necessary to interact with cytoskeletal, adaptor and signaling molecules to form focal adhesion [49]. More than 200 components have been found at focal adhesions [50], including different receptor classes, linker molecules, GTPases, kinases, and phosphatases, collectively known as the adhesome. Focal adhesion provides a physical connection for podocytes to adhere to the GBM and regulates intracellular and extracellular signal transduction and actin network remodeling, thus controlling cell functions and morphologies [51]. Integrin activation is essential for the initiation of focal adhesions [52]. Talin is a large, 270 kDa protein with 18 domains and binds to at least 11 different focal adhesion components [53]. Compared with other focal adhesion proteins, talin has a special role as it binds to the cytoplasmic domain of the β integrin subunit, thereby activating the entire integrin that is capable of high-affinity interactions with extracellular matrix ligands [54]. At the same time, the active talin engaged with integrin can span the entire structure of focal adhesion, not only can mediate the signal transmission from the inside out but also to act as a mechanical sensor, which is essential for regulating the maturity and stability of focal adhesion [55, 56]. Studies have shown that the absence of β1 or α3 integrin in podocytes can lead to severe proteinuria [57, 58], and abnormal loss of talin1 affects the activation of β1 integrin, adhesion complex dynamics, and adhesion ability [8]. To ascertain the importance of proteins regulating focal adhesion in podocyte, we interrogated the Nephroseq v5 transcriptomic database. We observed that there was a striking negative correlation between the glomerular TLN1 (talin1) expression with the body weight in db/db mice (Figure S4). Our results showed that TSF could significantly improve the body weight of db/db mice, while the irbesartan treatment did not exhibit the effect on the body weight of db/db mice. Furthermore, we observed that the glomerular TLN1 expression negatively correlated with an increase of serum creatinine in the chronic kidney disease (CKD) cohort (Figure S4), our previous work demonstrated that TSF could significantly improve the serum creatinine level in the DKD patients [14]. These findings provided the impetus to further examine the importance of glomerular talin1 in the pathogenesis of DKD.

Talin1 has a strong positive correlation with the severity of proteinuria, reduction in cell adhesion, and podocyte actin-cytoskeletal disorganization [8]. To the best of our knowledge, our research is the first to explore the role of podocyte talin1 in DKD. We initially found that there was a significant loss in podocyte talin1 in db/db mice and AGEs-stimulated primary mice podocyte, which could be restored by TSF treatment. Meanwhile, increased cell migration and actin-cytoskeleton rearrangement caused by reduced talin1 were also seen in AGEs-induced primary mice podocytes. Talin1 in podocytes appears to be an important factor in the pathogenesis of DKD. As the key adhesion protein of the cell-matrix adhesion complexes, talins bind and activate integrins, coupling them to the actin cytoskeleton [59]. The two isoforms of talins in vertebrates are talin1 and talin2. Talin1 is closely linked to cell adhesion [60] and early embryonic development [61]. Talin1 function most likely predominates in normal podocyte physiology based on the evidence that podocyte-specific deletion of talin1 leads to severe podocyte injury and progressive proteinuria, while ablation of podocyte talin2 in mice lacking talin1 does not significantly change its phenotype [8].

AGEs are the nonenzymatic glycation of proteins caused by the long-term high glucose levels. AGEs have been demonstrated to be closely related to the development and progression of DKD, and can be involved in podocyte injury, endothelial cell damage, and renal fibrosis, and ultimately lead to impaired renal function [41, 42]. AGEs have been extensively used to explore the mechanism of podocyte injury in DKD. The enhancement of podocyte migration ability has been implicated as an injury phenotype. In renal pathology induced by adriamycin or unilateral ureteral ligation, dynamic podocyte movement can be observed [62]. Pan and colleagues [63] showed that SRGAP2a expression in podocytes of DKD patients and db/db mice was significantly reduced compared to normal controls. Overexpression of SRGAP2a could reverse previously abnormal actin cytoskeletal rearrangement, inhibit podocyte migration, and alleviate foot process effacement by inhibiting over-activated Rho A and Cdc42. In this study, we found that AGEs caused an abnormal increase in podocyte migration. We also observed increased formation of lamellipodia and filopodia, suggesting that rearrangement of the actin cytoskeleton in podocytes could be induced by AGEs. These findings are consistent with previously published reports [6467]. The decreased expressions of talin1, integrin β1, and paxillin in primary mice podocytes after treatment with AGEs suggested that AGEs could cause the impairment in the cell-matrix adhesion ability of podocytes. TSF had a significant effect on the improvement of expressions of talin1, integrin β1, and paxillin in podocytes damaged by AGE stimulation. TSF also inhibited the migration phenotype of podocytes and alleviated the disorder of actin cytoskeleton. These effects of TSF are beneficial to the maintenance of the glomerular filtration barrier by improving the adhesion ability of podocytes.

Podocyte hypertrophy, foot process effacement, and the loss of podocytes in DKD are closely related to the abnormal expression of TRPC6 in podocytes, but little is known about its mechanism [68]. Cleavage of talin1 has been shown to be associated with TRPC6-dependent Ca2+ accumulation in podocyte injury [13]. Also, knockdown of TRPC6 also led to decreased cleavage of talin1 [9]. This suggests that TRPC6-dependent Ca2+ accumulation is involved in the cleavage of talin1. Chen and colleagues [69] demonstrated that AGEs could induce an increase in [Ca2+]i through influx of extracellular Ca2+ in podocytes. However, little is known about the relationship between AGEs and TRPC6 in this pathophysiologic process. In the current study, we found increased TRPC6 expression in both db/db mice and AGEs-stimulated primary mice podocytes. The intracellular Ca2+ level of podocytes regulated by TRPC6 plays a key role in maintaining the stability of the actin-cytoskeleton structure and podocyte injury [70]. Although the mechanism for TRPC6 activation remains unclear, abnormal changes in angiotensin II and reactive oxygen species (ROS) in the DKD setting can stimulate overexpression of TRPC6 in podocytes. This causes a large amount of Ca2+ influx into podocytes, resulting in foot process effacement, podocyte loss, and other damage, which eventually leads to proteinuria development. Our results showed that there was a significant increase in Ca2+ level in AGEs-treated podocytes compared with the control, and this increase was attenuated by TSF and the TRPC6 inhibitor SAR7334. This indicated that increased intracellular Ca2+ accumulation induced by TRPC6 is involved in podocyte injury caused by AGEs, and that TSF could reduce TRPC6-mediated Ca2+ accumulation.

Decrease in talin1 protein, increase in cell migration, and disorganization of F-actin in podocytes were also observed with the activation of TRPC6. The F-actin pattern determined by phalloidin staining transformed from more than 90% of cell area filled with thick cables or at least two thick cables running under the nucleus into no thick cables or no cables visible in the central area of the cell after the podocytes were stimulated by AGEs. These pattern changes are similar to the results reported in other studies, that TRPC6 KO podocytes display less motility, more adhesiveness and more actin stress fibers. These changes are alleviated after the reexpression of wtTRPC6 [9]. However, previous studies also showed the role of TRPC6 in regulating Rho A activation, stress fiber contraction, and motility [71, 72]. This difference may be attributed to the difference in TRPC6 knockout level caused by siRNA technology used in previous studies, where some preservation of expression is seen. Our in vitro cell culture results showed that TSF could inhibit the increase in TRPC6 expression, decrease in talin1, and disorganization of actin-cytoskeleton. This effect could also be attenuated by the TRPC6 agonist OAG. These results suggest that TSF protects talin1 by inhibiting TRPC6 activation. Although much progress has been made in the development of TRPC6 agonists, either OAG, GSK1702934A [73], piperazine derivatives [74], or pyrazolopyrimidines [75], subtype selectivity is still lacking within the TRPC3/6/7 group of ion channels. Thus, further studies and more convincing evidence are needed to elucidate the protective effect of TSF on talin1 by inhibiting TRPC6 activation in podocytes.

Additionally, we observed an increase in NFATC2 entry into nuclei in AGEs-stimulated primary mice podocytes, but not NFATC3. The NFATC family (including NFATC1 through NFATC4) is usually located in the cytoplasm as a potential form of hyperphosphorylation [76] and is mainly regulated by serine/threonine phosphatase calcineurin. Upon activation, NFATCs can undergo dephosphorylation into the nucleus to perform their functions. The important transcriptional target of NFATCs is TRPC6 itself, which results in a harmful feedforward loop [77]. NFATCs are expressed in a variety of cell types, including podocytes. It has been shown that NFATC2 podocyte-specific overexpression leads to proteinuria and glomerular sclerosis [78]. Further studies [79, 80] have also found a significant increase in NFATC2 activation in podocytes of db/db mice and could be inhibited by the NFAT inhibitor peptide (11R-VIVIT). High glucose-induced mice podocytes also activate NFATC2 in a time- and dose-dependent manner and is prevented by Nfatc2 gene knockdown. In our study, AGEs-stimulated primary mice podocytes increased intracellular Ca2+ concentration, leading to subsequent nuclear accumulation of NFATC2. We only explored the occurrences in NFATC2 and 3, as abundant literature on these two proteins provided the foundation for our investigation. Given our findings, we believe that TRPC6-dependent Ca2+ accumulation is involved in DKD podocyte injury, and the protective effect of TSF on podocytes may be through inhibition of TRPC6 activation and protection of talin1 from loss. However, TSF is a complex Chinese Medicine compound with multiple active ingredients. It is indeed difficult to accurately explain the protective effect of TSF on DKD with one mechanism. Therefore, it is important to explore all the possible biochemical interactions of TSF in podocytes and to clarify how the compounds interact with podocytes. This will be the focus of our further research.

5. Conclusion

In conclusion, the present study demonstrated that TSF could alleviate podocyte injury and reduce proteinuria induced by DKD, the mechanism of which might be mediated by the regulation of TRPC6/Talin1 pathway in podocytes, following an improvement in the podocyte-matrix adherence. These findings may be beneficial to our understanding of the role of TSF in protecting podocytes and further enrich our knowledge of the mechanism of podocyte injury in DKD.

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Ethical Approval

The animal study was reviewed and approved by the Ethics Committee of the China-Japan Friendship Institute of Clinical Medical Sciences, Beijing, China.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

TZ and PL designed the experiments. HJZ and WZ performed the herbal preparation. QW, YW, and HLZ conducted the experiments. JL and XZ analyzed the data. QW and XT wrote the manuscript. All authors read and approved the manuscript.

Acknowledgments

We are very grateful to Dr. Shuta Ishibe’s laboratory at the Yale School of Medicine for kindly providing us the protocol of primary mice podocytes culture. Thanks to Professor Qionglin Liang and Researcher Zixing Shao of Tsinghua University for their help in screening the effective ingredients of TSF. This work was funded by the following sources: National Natural Science Foundation of China grants 81620108031 (Dr. Ping Li) and 81973627 (Dr. Tingting Zhao). The authors thank Nissi S. Wang, MSc, for the content editing of the manuscript.

Supplementary Materials

Table S1: compounds detected in TSF. Table S2: compounds detected in the serum of TSF treated mice. Figure S1: immunoblotting of TRPC6 and talin1 in MPC5 cells treated with scramble siRNA or Trpc6 siRNA. Figure S2: immunohistochemical staining and quantitative analysis of collagen type I. Figure S3: the effect of irbesartan in combination with AGEs in wound healing assay. Figure S4: glomerular TLN1 expression in db/db mice and CKD patients. (Supplementary Materials)

References

  1. R. Z. Alicic, M. T. Rooney, and K. R. Tuttle, “Diabetic kidney disease: challenges, progress, and possibilities,” Clinical Journal of the American Society of Nephrology: CJASN, vol. 12, no. 12, pp. 2032–2045, 2017. View at: Publisher Site | Google Scholar
  2. A. Greka and P. Mundel, “Cell biology and pathology of podocytes,” Annual Review of Physiology, vol. 74, no. 1, pp. 299–323, 2012. View at: Publisher Site | Google Scholar
  3. W. H. Fissell and J. H. Miner, “What is the glomerular ultrafiltration barrier?” Journal of Cell Biology, vol. 29, no. 9, pp. 2262–2264, 2018. View at: Publisher Site | Google Scholar
  4. C. Faul, K. Asanuma, E. Yanagida-Asanuma, K. Kim, and P. Mundel, “Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton,” Trends in Cell Biology, vol. 17, no. 9, pp. 428–437, 2007. View at: Publisher Site | Google Scholar
  5. Y. Maezawa and K. Yokote, “Human glomerular transcriptome of diabetic kidneys: can the podocyte cytoskeleton be a therapeutic target?” Journal of Diabetes Investigation, vol. 10, no. 2, pp. 224–226, 2019. View at: Publisher Site | Google Scholar
  6. C. Schell and T. B. Huber, “The evolving complexity of the podocyte cytoskeleton,” Journal of the American Society of Nephrology: JASN, vol. 28, no. 11, pp. 3166–3174, 2017. View at: Publisher Site | Google Scholar
  7. D. Cox, M. Brennan, and N. Moran, “Integrins as therapeutic targets: lessons and opportunities,” Nature Reviews Drug Discovery, vol. 9, no. 10, pp. 804–820, 2010. View at: Publisher Site | Google Scholar
  8. X. Tian, J. J. Kim, S. M. Monkley et al., “Podocyte-associated talin 1 is critical for glomerular filtration barrier maintenance,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 1098–1113, 2014. View at: Publisher Site | Google Scholar
  9. L. K. Farmer, R. Rollason, D. J. Whitcomb et al., “TRPC6 binds to and activates calpain, independent of its channel activity, and regulates podocyte cytoskeleton, cell adhesion, and motility,” Journal of the American Society of Nephrology: JASN, vol. 30, no. 10, pp. 1910–1924, 2019. View at: Publisher Site | Google Scholar
  10. M. P. Winn, P. J. Conlon, K. L. Lynn et al., “A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis,” Science, vol. 308, no. 5729, pp. 1801–1804, 2005. View at: Publisher Site | Google Scholar
  11. D. Rogacka, I. Audzeyenka, P. Rachubik et al., “Insulin increases filtration barrier permeability via TRPC6-dependent activation of PKGIα signaling pathways,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1863, no. 6, pp. 1312–1325, 2017. View at: Publisher Site | Google Scholar
  12. J. S. Kang, S. J. Lee, J. H. Lee et al., “Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease,” Scientific Reports, vol. 9, no. 1, p. 7679, 2019. View at: Publisher Site | Google Scholar
  13. K. A. T. Verheijden, R. Sonneveld, M. Bakker-van Bebber, J. F. M. Wetzels, J. van der Vlag, and T. Nijenhuis, “The calcium-dependent protease calpain-1 links TRPC6 activity to podocyte injury,” Journal of the American Society of Nephrology: JASN, vol. 29, no. 8, pp. 2099–2109, 2018. View at: Publisher Site | Google Scholar
  14. P. Li, Y. Chen, J. Liu et al., “Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial,” PLoS One, vol. 10, no. 5, article e0126027, 2015. View at: Publisher Site | Google Scholar
  15. M. Li, W. Wang, J. Xue, Y. Gu, and S. Lin, “Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 412–419, 2011. View at: Publisher Site | Google Scholar
  16. G. H. Baek, Y. S. Jang, S. I. Jeong et al., “Rehmannia glutinosa suppresses inflammatory responses elicited by advanced glycation end products,” Inflammation, vol. 35, no. 4, pp. 1232–1241, 2012. View at: Publisher Site | Google Scholar
  17. T. Zhao, H. Zhang, X. Yin et al., “Tangshen formula modulates gut Microbiota and reduces gut-derived toxins in diabetic nephropathy rats,” Biomedicine & Pharmacotherapy, vol. 129, p. 110325, 2020. View at: Publisher Site | Google Scholar
  18. Q. Kong, H. Zhang, T. Zhao et al., “Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice,” International Journal of Molecular Medicine, vol. 38, no. 6, pp. 1715–1726, 2016. View at: Publisher Site | Google Scholar
  19. K. Liu, H. Xu, G. Lv et al., “Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products,” Life Sciences, vol. 123, pp. 78–85, 2015. View at: Publisher Site | Google Scholar
  20. W. L. Jiang, S. P. Zhang, J. Hou, and H. B. Zhu, “Effect of loganin on experimental diabetic nephropathy,” Phytomedicine, vol. 19, no. 3-4, pp. 217–222, 2012. View at: Publisher Site | Google Scholar
  21. D. Tang, B. He, Z. G. Zheng et al., “Inhibitory effects of two major isoflavonoids in Radix Astragali on high glucose-induced mesangial cells proliferation and AGEs-induced endothelial cells apoptosis,” Planta Medica, vol. 77, no. 7, pp. 729–732, 2011. View at: Publisher Site | Google Scholar
  22. M. J. Oza and Y. A. Kulkarni, “Formononetin attenuates kidney damage in type 2 diabetic rats,” Life Sciences, vol. 219, pp. 109–121, 2019. View at: Publisher Site | Google Scholar
  23. J. Zhang, S. Yang, H. Li, F. Chen, and J. Shi, “Naringin ameliorates diabetic nephropathy by inhibiting NADPH oxidase 4,” European Journal of Pharmacology, vol. 804, pp. 1–6, 2017. View at: Publisher Site | Google Scholar
  24. S. Jia, Y. Hu, W. Zhang et al., “Hypoglycemic and hypolipidemic effects of neohesperidin derived from Citrus aurantium L. in diabetic KK-A (y) mice,” Food & Function, vol. 6, no. 3, pp. 878–886, 2015. View at: Publisher Site | Google Scholar
  25. Q. Zhang, L. Liu, W. Lin et al., “Rhein reverses Klotho repression via promoter demethylation and protects against kidney and bone injuries in mice with chronic kidney disease,” Kidney International, vol. 91, no. 1, pp. 144–156, 2017. View at: Publisher Site | Google Scholar
  26. S. Duan, Y. Wu, C. Zhao et al., “The wnt/β-catenin signaling pathway participates in rhein ameliorating kidney injury in DN mice,” Molecular and Cellular Biochemistry, vol. 411, no. 1-2, pp. 73–82, 2016. View at: Publisher Site | Google Scholar
  27. H. Zhang, P. Li, F. J. Burczynski et al., “Attenuation of diabetic nephropathy in Otsuka long-evans Tokushima fatty (OLETF) rats with a combination of Chinese herbs (tangshen formula),” Evidence-based Complementary and Alternative Medicine: Ecam, vol. 2011, article 613737, 8 pages, 2011. View at: Publisher Site | Google Scholar
  28. T. Zhao, S. F. Sun, H. J. Zhang et al., “Therapeutic Effects of Tangshen Formula on Diabetic Nephropathy in Rats,” PLoS One, vol. 11, no. 1, article e0147693, 2016. View at: Publisher Site | Google Scholar
  29. H. Zhao, X. Li, T. Zhao et al., “Tangshen formula attenuates diabetic renal injuries by upregulating autophagy via inhibition of PLZF expression,” PLoS One, vol. 12, no. 2, article e0171475, 2017. View at: Publisher Site | Google Scholar
  30. K. Sharma, P. McCue, and S. R. Dunn, “Diabetic kidney disease in the db/db mouse,” American Journal of Physiology. Renal Physiology, vol. 284, no. 6, pp. F1138–F1144, 2003. View at: Publisher Site | Google Scholar
  31. G. E. Truett, R. J. Tempelman, J. A. Walker, and J. K. Wilson, “Misty (m) affects growth traits,” American Journal of Physiology, vol. 275, no. 1, pp. R29–R32, 1998. View at: Publisher Site | Google Scholar
  32. H. Zhang, H. M. Zhang, L. P. Wu et al., “Impaired mitochondrial complex III and melatonin responsive reactive oxygen species generation in kidney mitochondria of db/db mice,” Journal of Pineal Research, vol. 51, no. 3, pp. 338–344, 2011. View at: Publisher Site | Google Scholar
  33. S. Reagan-Shaw, M. Nihal, and N. Ahmad, “Dose translation from animal to human studies revisited,” The FASEB Journal, vol. 22, no. 3, pp. 659–661, 2007. View at: Publisher Site | Google Scholar
  34. H. Cheng, H. Wang, X. Fan, P. Paueksakon, and R. C. Harris, “Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice,” Kidney International, vol. 82, no. 11, pp. 1176–1183, 2012. View at: Publisher Site | Google Scholar
  35. S. Majumder, M. J. Hadden, K. Thieme et al., “Dysregulated expression but redundant function of the long non-coding RNA HOTAIR in diabetic kidney disease,” Diabetologia, vol. 62, no. 11, pp. 2129–2142, 2019. View at: Publisher Site | Google Scholar
  36. K. Soda, D. M. Balkin, S. M. Ferguson et al., “Role of dynamin, synaptojanin, and endophilin in podocyte foot processes,” The Journal of Clinical Investigation, vol. 122, no. 12, pp. 4401–4411, 2012. View at: Publisher Site | Google Scholar
  37. H. Ma, A. Togawa, K. Soda et al., “Inhibition of podocyte FAK protects against proteinuria and foot process effacement,” Journal of the American Society of Nephrology: JASN, vol. 21, no. 7, pp. 1145–1156, 2010. View at: Publisher Site | Google Scholar
  38. G. Grynkiewicz, M. Poenie, and R. Y. Tsien, “A new generation of Ca2+ indicators with greatly improved fluorescence properties,” Journal of Biological Chemistry, vol. 260, no. 6, pp. 3440–3450, 1985. View at: Google Scholar
  39. J. Wu, C. Zheng, X. Wang et al., “MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytes,” Journal of Clinical Investigation, vol. 125, no. 11, pp. 4091–4106, 2015. View at: Publisher Site | Google Scholar
  40. P. Liu, L. Peng, H. Zhang et al., “Tangshen formula attenuates diabetic nephropathy by promoting ABCA1-mediated renal cholesterol efflux in db/db mice,” Frontiers in Physiology, vol. 9, p. 343, 2018. View at: Publisher Site | Google Scholar
  41. T. Wendt, N. Tanji, J. Guo et al., “Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy,” Journal of the American Society of Nephrology: JASN, vol. 14, no. 5, pp. 1383–1395, 2003. View at: Publisher Site | Google Scholar
  42. X. Zhao, Y. Chen, X. Tan et al., “Advanced glycation end-products suppress autophagic flux in podocytes by activating mammalian target of rapamycin and inhibiting nuclear translocation of transcription factor EB,” Journal of Pathology, vol. 245, no. 2, pp. 235–248, 2018. View at: Publisher Site | Google Scholar
  43. X. Zhang, G. Jiang, Y. Cai, S. J. Monkley, D. R. Critchley, and M. P. Sheetz, “Talin depletion reveals independence of initial cell spreading from integrin activation and traction,” Nature Cell Biology, vol. 10, no. 9, pp. 1062–1068, 2008. View at: Publisher Site | Google Scholar
  44. H. Zhou, X. Tian, A. Tufro, G. Moeckel, S. Ishibe, and J. Goodwin, “Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury,” Scientific Reports, vol. 7, no. 1, p. 9833, 2017. View at: Publisher Site | Google Scholar
  45. T. Maier, M. Follmann, G. Hessler et al., “Discovery and pharmacological characterization of a novel potent inhibitor of diacylglycerol-sensitive TRPC cation channels,” British Journal of Pharmacology, vol. 172, no. 14, pp. 3650–3660, 2015. View at: Publisher Site | Google Scholar
  46. W. Kriz, I. Shirato, M. Nagata, M. LeHir, and K. V. Lemley, “The podocyte’s response to stress: the enigma of foot process effacement,” American Journal of Physiology Renal Physiology, vol. 304, no. 4, pp. F333–F347, 2013. View at: Publisher Site | Google Scholar
  47. R. Lennon, M. J. Randles, and M. J. Humphries, “The importance of podocyte adhesion for a healthy glomerulus,” Frontiers in Endocrinology, vol. 5, no. 14, p. 160, 2014. View at: Publisher Site | Google Scholar
  48. W. Kriz and K. V. Lemley, “A potential role for mechanical forces in the detachment of podocytes and the progression of CKD,” Journal of the American Society of Nephrology: JASN, vol. 26, no. 2, pp. 258–269, 2015. View at: Publisher Site | Google Scholar
  49. H. B. Schiller, C. C. Friedel, C. Boulegue, and R. Fässler, “Quantitative proteomics of the integrin adhesome show a myosin II-dependent recruitment of LIM domain proteins,” EMBO Reports, vol. 12, no. 3, pp. 259–266, 2011. View at: Publisher Site | Google Scholar
  50. S. E. Winograd-Katz, R. Fässler, B. Geiger, and K. R. Legate, “The integrin adhesome: from genes and proteins to human disease,” Nature Reviews Molecular Cell Biology, vol. 15, no. 4, pp. 273–288, 2014. View at: Publisher Site | Google Scholar
  51. R. O. Hynes, “Integrins: bidirectional, allosteric signaling machines,” Cell, vol. 110, no. 6, pp. 673–687, 2002. View at: Publisher Site | Google Scholar
  52. B. Geiger, J. P. Spatz, and A. D. Bershadsky, “Environmental sensing through focal adhesions,” Nature Reviews Molecular Cell Biology, vol. 10, no. 1, pp. 21–33, 2009. View at: Publisher Site | Google Scholar
  53. B. T. Goult, J. Yan, and M. A. Schwartz, “Talin as a mechanosensitive signaling hub,” Journal of Cell Biology, vol. 217, no. 11, pp. 3776–3784, 2018. View at: Publisher Site | Google Scholar
  54. K. L. Wegener, A. W. Partridge, J. Han et al., “Structural basis of integrin activation by talin,” Cell, vol. 128, no. 1, pp. 171–182, 2007. View at: Publisher Site | Google Scholar
  55. D. S. Harburger and D. A. Calderwood, “Integrin signalling at a glance,” Journal of Cell Science, vol. 122, no. 2, pp. 159–163, 2008. View at: Publisher Site | Google Scholar
  56. A. Kumar, M. Ouyang, K. Van den Dries et al., “Talin tension sensor reveals novel features of focal adhesion force transmission and mechanosensitivity,” Journal of Cell Biology, vol. 213, no. 3, pp. 371–383, 2016. View at: Publisher Site | Google Scholar
  57. A. Pozzi, G. Jarad, G. W. Moeckel et al., “Beta 1 integrin expression by podocytes is required to maintain glomerular structural integrity,” Developmental Biology, vol. 316, no. 2, pp. 288–301, 2008. View at: Publisher Site | Google Scholar
  58. N. Sachs, M. Kreft, M. A. van den Bergh Weerman et al., “Kidney failure in mice lacking the tetraspanin CD151,” Journal of Cell Biology, vol. 175, no. 1, pp. 33–39, 2006. View at: Publisher Site | Google Scholar
  59. R. E. Gough and B. T. Goult, “The tale of two talins - two isoforms to fine-tune integrin signalling,” FEBS Letters, vol. 592, no. 12, pp. 2108–2125, 2018. View at: Publisher Site | Google Scholar
  60. A. M. Manso, H. Okada, F. M. Sakamoto et al. et al., “Loss of mouse cardiomyocyte talin-1 and talin-2 leads to β-1 integrin reduction, costameric instability, and dilated cardiomyopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 30, pp. E6250–E6259, 2017. View at: Publisher Site | Google Scholar
  61. S. J. Monkley, X. H. Zhou, S. J. Kinston et al., “Disruption of the talin gene arrests mouse development at the gastrulation stage,” Developmental Dynamics: an Official Publication of the American Association of Anatomists, vol. 219, no. 4, pp. 560–574, 2000. View at: Publisher Site | Google Scholar
  62. M. J. Hackl, J. L. Burford, K. Villanueva et al., “Tracking the fate of glomerular epithelial cells in vivo using serial multiphoton imaging in new mouse models with fluorescent lineage tags,” Nature Medicine, vol. 19, no. 12, pp. 1661–1666, 2013. View at: Publisher Site | Google Scholar
  63. Y. Pan, S. Jiang, Q. Hou et al., “Dissection of glomerular transcriptional profile in patients with diabetic nephropathy: SRGAP2a protects podocyte structure and function,” Diabetes, vol. 67, no. 4, pp. 717–730, 2018. View at: Publisher Site | Google Scholar
  64. H. L. Kuo, C. C. Huang, T. Y. Lin, and C. Y. Lin, “IL-17 and CD40 ligand synergistically stimulate the chronicity of diabetic nephropathy,” Nephrology, Dialysis, Transplantation, vol. 33, no. 2, pp. 248–256, 2018. View at: Publisher Site | Google Scholar
  65. Y. Chen, J. Chen, M. Jiang et al., “Loganin and catalpol exert cooperative ameliorating effects on podocyte apoptosis upon diabetic nephropathy by targeting AGEs-RAGE signaling,” Life Sciences, vol. 252, p. 117653, 2020. View at: Publisher Site | Google Scholar
  66. Q. Wang, Z. Shen, G. Qi, Y. Zhao, H. Zhang, and R. Wang, “Thymol alleviates AGEs-induced podocyte injury by a pleiotropic effect via NF-κB-mediated by RhoA/ROCK signalling pathway,” Cell Adhesion & Migration, vol. 14, no. 1, pp. 42–56, 2020. View at: Publisher Site | Google Scholar
  67. C. Cheng, Z. Zheng, C. Shi, X. Liu, Z. Ye, and T. Lou, “Advanced glycation end-products reduce podocyte adhesion by activating the renin-angiotensin system and increasing integrin-linked kinase,” Experimental and Therapeutic Medicine, vol. 6, no. 6, pp. 1494–1498, 2013. View at: Publisher Site | Google Scholar
  68. A. Staruschenko, D. Spires, and O. Palygin, “Role of TRPC6 in Progression of Diabetic Kidney Disease,” Current Hypertension Reports, vol. 21, no. 7, p. 48, 2019. View at: Publisher Site | Google Scholar
  69. Y. Chen, C. P. Liu, K. F. Xu et al., “Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by advanced glycation end products in cultured mouse podocytes,” American Journal of Nephrology, vol. 28, no. 6, pp. 1014–1022, 2008. View at: Publisher Site | Google Scholar
  70. D. V. Ilatovskaya and A. Staruschenko, “TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases,” American Journal of Physiology. Renal Physiology, vol. 309, no. 5, pp. F393–F397, 2015. View at: Publisher Site | Google Scholar
  71. D. Tian, S. M. P. Jacobo, D. Billing et al., “Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels,” Science Signaling, vol. 3, no. 145, article ra77, 2010. View at: Publisher Site | Google Scholar
  72. S. Park, S. Lee, E. J. Park et al., “TGFβ1 induces stress fiber formation through upregulation of TRPC6 in vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 483, no. 1, pp. 129–134, 2017. View at: Publisher Site | Google Scholar
  73. X. Xu, I. Lozinskaya, M. Costell et al., “Characterization of small molecule TRPC3 and TRPC6 agonist and antagonists,” Biophysical Journal, vol. 104, no. 2, p. 454a, 2013. View at: Publisher Site | Google Scholar
  74. S. Sawamura, M. Hatano, Y. Takada et al., “Screening of transient receptor potential canonical channel activators identifies novel neurotrophic piperazine compounds,” Molecular Pharmacology, vol. 89, no. 3, pp. 348–363, 2016. View at: Publisher Site | Google Scholar
  75. C. Qu, M. Ding, Y. Zhu et al., “Pyrazolopyrimidines as potent stimulators for transient receptor potential canonical 3/6/7 channels,” Journal of Medicinal Chemistry, vol. 60, no. 11, pp. 4680–4692, 2017. View at: Publisher Site | Google Scholar
  76. A. Rao, C. Luo, and P. G. Hogan, “Transcription factors of the NFAT family: regulation and function,” Annual Review of Immunology, vol. 15, no. 1, pp. 707–747, 1997. View at: Publisher Site | Google Scholar
  77. T. Nijenhuis, A. J. Sloan, J. G. J. Hoenderop et al., “Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway,” American Journal of Physiology, vol. 179, no. 4, pp. 1719–1732, 2011. View at: Publisher Site | Google Scholar
  78. Y. Wang, G. Jarad, P. Tripathi et al., “Activation of NFAT signaling in podocytes causes glomerulosclerosis,” Journal of the American Society of Nephrology: JASN, vol. 21, no. 10, pp. 1657–1666, 2010. View at: Publisher Site | Google Scholar
  79. L. Zhang, R. Li, W. Shi et al., “NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice,” British Journal of Pharmacology, vol. 170, no. 2, pp. 426–439, 2013. View at: Publisher Site | Google Scholar
  80. R. Li, L. Zhang, W. Shi et al., “NFAT2 mediates high glucose-induced glomerular podocyte apoptosis through increased Bax expression,” Experimental Cell Research, vol. 319, no. 7, pp. 992–1000, 2013. View at: Publisher Site | Google Scholar

Copyright © 2020 Qian Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views345
Downloads279
Citations

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.